Tropical Medicine & International Health

European Union’s research policy: a moving target?
pp. 843-844(2)
Authors: Boelaert M.; Matthys F.; Henkens M.; D'Alessandro U.

History and importance of antimalarial drug resistance
pp. 845-848(4)
Authors: D'Alessandro U.; Buttiëns H.

Drug resistance in Indian visceral leishmaniasis
pp. 849-854(6)
Author: Sundar S.

Trypanosomiase humaine africaine: historique de la thérapeutique et de ses échecs
pp. 855-863(9)
Authors: Ollivier G.; Legros D.

Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence
pp. 864-873(10)
Authors: Gryseels B.; Mbaye A.; De Vlas S.J.; Stelma F.F.; Guissé F.; Van Lieshout L.; Faye D.; Diop M.; Ly A.; Tchuem-Tchuenté L.A.; Engels D.; Polman K.

Biochemical and molecular mechanisms of drug resistance in parasites
pp. 874-882(9)
Author: Ouellette M.

Modelling parasite drug resistance: lessons for management and control strategies
pp. 883-890(8)
Author: Hastings I.M.

Monitoring antimalarial drug resistance within National Malaria Control Programmes: the EANMAT experience
pp. 891-898(8)

Monitoring drug resistance in leishmaniasis
pp. 899-905(7)
Author: Croft S.L.

The phenomenon of treatment failures in Human African Trypanosomiasis
pp. 906-914(9)
Authors: Brun R.; Schumacher R.; Schmid C.; Kunz C.; Burri C.

Anthelmintic resistance in human helminths: a review
pp. 915-921(7)
Authors: Geerts S.; Gryseels B.

Controlling malaria: challenges and solutions
pp. 922-927(6)
Authors: Olliaro P.; Taylor W.R.J.; Rigal J.

A policy for leishmaniasis with respect to the prevention and control of drug resistance
pp. 928-934(7)
Author: Bryceson A.

Drug-based helminth control in Western Pacific countries: a general perspective
pp. 935-944(10)
Authors: Urbani C.; Palmer K.

Drugs for neglected diseases: a failure of the market and a public health failure?
pp. 945-951(7)
Authors: Trouiller P.; Torreele E.; Olliaro P.; White N.; Foster S.; Wirth D.; Pécoul B.

Chlorproguanil-dapsone (LAPDAP) for uncomplicated falciparum malaria
pp. 952-954(3)
Author: Winstanley P.

Introductory note: The access to Essential Medicines Campaign
pp. 955-956(2)
Authors: Kindermans J-M.; Matthys F.

Availability and affordability of treatment for Human African Trypanosomiasis
pp. 957-959(3)
Authors: Etchegorry M.G.; Helenport J.P.; Pecoul B.; Jannin J.; Legros D.

Pricing of drugs and donations: options for sustainable equity pricing
pp. 960-964(5)
Authors: Pérez-Casas C.; Herranz E.; Ford N.